4 min read
Trial Tuesday: Obesity's Next Tier Steps Up
Viking bets on fewer shots, while Roche bets on a better-engineered molecule, as both chase the next generation of obesity blockbusters.
Viking bets on fewer shots, while Roche bets on a better-engineered molecule, as both chase the next generation of obesity blockbusters.